# A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis

> **NCT00616434** · PHASE2 · COMPLETED · sponsor: **Biogen** · enrollment: 123 (actual)

## Conditions studied

- Active Ulcerative Colitis

## Interventions

- **DRUG:** BG9418 (Interferon beta-1a)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00616434
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2014-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00616434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00616434, "A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00616434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*